Boehringer Ingelheim Pharmaceuticals, Inc.

CT · United States · Reporting entity ID 100000000234

Total reported 2019–2025

$637.5M

#28 of 2,960 reporting companies — 0.8% of all reported industry payments

$119.3M in general payments across 1,407,196 records, plus $518.2M in research funding across 24,150 records.

How it breaks down

General payments $119,273,072

Research funding $518,217,143

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.